As of September 30, the company had approximately $12.9M in cash and investments, vs. $17.5M as of December 31, 2022. “We are pleased to report continued progress toward achieving meaningful milestones,” commented Gregory Gorgas, CEO. “Specifically, we are on track to complete patient enrollment in our Cancer Appetite Recovery Study Phase 2a trial, evaluating our lead clinical program ART27.13 for the treatment of cancer-related anorexia and weight loss, in the second half of next year. Furthermore, we maintained a strong balance sheet with over $12.9M in cash and cash equivalents, which we believe will support operations into 1Q25. We continue to carefully manage our resources in order to reach significant development milestones and attract partner interest across our entire portfolio”.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARTL:
- Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
- Artelo Biosciences announces publication of peer-reviewed research on ART27.13
- Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers
- Artelo Biosciences to present preclinical data on ART26.12
- Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023
